The management of spasticity

Drug and Therapeutics Bulletin

Volumn 38, Issue 6, 2000, Pages 44-46

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BENZODIAZEPINE DERIVATIVE; BOTULINUM TOXIN A; DANTROLENE; TIZANIDINE;

AFFECTIVE NEUROSIS; ANKYLOSIS; CLINICAL TRIAL; DIARRHEA; HALLUCINATION; HEPATITIS; HUMAN; INSOMNIA; MALAISE; MOTOR DYSFUNCTION; MUSCLE CONTRACTURE; MUSCLE SPASM; MUSCLE STIFFNESS; MUSCLE WEAKNESS; NAUSEA; NERVE BLOCK; NEUROLOGIC DISEASE; PATIENT CARE; PHYSIOTHERAPY; SHORT SURVEY; SLEEP DISORDER; SPASTICITY; SYMPTOM; TASTE DISORDER; VERTIGO;

EID: 0034053723     PISSN: 00126543     EISSN: None     Source Type: Journal    
DOI: 10.1136/dtb.2000.38644     Document Type: Short Survey

References (25)

1. Brown P. Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry 1994; 57: 773-7.
2. Ada L. Vattanasilp W, O'Dwyer NJ, Crosbie J. Does spasticity contribute to walking dysfunction after stroke? J Neurol Neurosurg Psychiatry 1998, 64: 628-35.
3. Young RR. Spasticity: a review. Neurology 1994; 44 (suppl 9): S12-20.
4. Tardieu C, Lespargot A, Tabary C, Bret MD. For how long must the soleus muscle be stretched each day to prevent contracture? Dev Med Child Neurol 1988; 30: 3-10.
5. Wilson LA, McKechnie AA. Oral diazepam in the treatment of spasticity in paraplegia. A double-blind trial and subsequent impressions. Scott Med J 1966; 11: 46-51.
6. Corbett M, Frankel HL, Michaelis L. A double-blind, cross-over trial of valium in the treatment of spasticity. Paraplegia 1972; 10: 19-22.
7. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000; 59: 487-95.
8. Cartlidge NEF, Hudgson P, Weightman D. A comparison of baclofen and diazepam in the treatment of spasticity. J Neurol Sci 1974; 23: 17-24.
9. Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986; 32: 130-68.
10. Schmidt RT, Lee RH, Spehlmann R. Comparison of dantrolene sodium and diazepam in the treatment of spasticity. J Neurol Neurosurg Psychiatry 1976; 39: 350-6.
11. The United Kingdom Tizanidine Trial Group. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994; 44 (suppl 9): S70-8.
12. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD and the US Tizanidine Study Group. Tizanidine treatment of spasticity caused by multiple sclerosis. results of a double-blind, placebo-controlled trial. Neurology 1994; 44 (suppl 9): S34-43.
13. Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Martinez-Arizala A and the North American Tizanidine Study Group. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury Neurology 1994; 44 (suppl 9): S44-52.
14. Wallace JD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 1994; 44 (suppl 9): S60-9.
15. Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997; 53: 435-52.
16. Ordia JI, Fischer E, Adamski E, Spatz EL. Chronic intrathecal delivery of baclofen by a programmable pump for the treatment of severe spasticity. J Neurosurg 1996; 85: 452-7.
17. Middel B, Kuipers-Upmeijer H, Bouma J, Staal M et al. Effect of intrathecal baclofen delivered by an implantable programmable pump on health related quality of life in patients with severe spasticity. J Neurol Neurosurg Psychiatry 1997; 63: 204-9.
18. Creedon SD, Dijkers MPJM, Hinderer SR. Intrathecal baclofen for severe spasticity: a meta-analysis. Int J Rehabil Health 1997; 3: 171-85.
19. Rawicki B. Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: long-term follow-up review of 18 patients. J Neurosurg 1999; 91: 733-6.
20. Teddy P, Jamous A, Gardner B, Wang D, Silver J. Complications of intrathecal baclofen delivery. Br J Neurosurg 1992; 6: 115-8.
21. Boyd R, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: indications and outcomes. Eur J Neurol 1987; 4 (suppl 2): S15-22.
22. Burbaud P, Wiart L, Dubos JL et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996; 61. 265-9.
23. Corry IS, Cosgrove AP, Walsh EG, McClean D, Graham HK. Botulinum toxin A in the hemiplegic upper limb. a double-blind trial. Dev Med Child Neural 1997; 39: 185-93.
24. Smith SJ, Ellis E, White S, Moore AP. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury. Clin Rehabil 2000; 14: 5-13.
25. Koman LA, Mooney JF, Smith BP, Walker F, Leon JM and the BOTOX Study Group. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop 2000; 20: 108-15.